Clinical trial
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological…
NCT00308048 · Ullevaal University Hospital, Other · Completed
Key facts
| NCT number | NCT00308048 |
|---|---|
| Title | 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response |
| Official title | 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response |
| Lead sponsor | Ullevaal University Hospital, Other |
| Collaborators | Schering-Plough Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis C Virus Infection |
| Intervention type | Drug |
| Interventions | Pegylated Interferon alfa 2b and ribavirin |
| Enrollment | 435 |
| Start date | Mar 1, 2004 |
| Completion | Sep 1, 2006 |
| First posted | Mar 28, 2006 |
| Last update posted | Jul 6, 2011 |
| Countries | Norway |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: